Allergan, Inc. AGN
Allergan shareholders should accept Valeant's bid: Valeant is an 'Outsider'-style acquirer (25x TSR under Pearson) whose lean R&D and platform M&A will compound Val-gan's value far beyond Allergan standalone.
Thesis
Pershing Square — Allergan's largest shareholder with a 9.7% stake — has partnered with Valeant Pharmaceuticals to acquire Allergan in a cash-and-stock deal worth roughly $48.30 plus 0.83 Valeant shares per Allergan share. The argument frames Valeant CEO Mike Pearson as a modern 'Outsider' in the Buffett/Singleton/Murphy/Malone tradition whose disciplined M&A platform produced a 25x total return since 2008 by combining lean ~3% R&D, decentralized operations, zero-based SG&A, and over 100 accretive acquisitions totaling $19bn+. Inside Val-gan, Allergan's durable franchises (Botox, eye care, aesthetics) would shed traditional-pharma overhead and compound at industry-leading ~50% EBIT margins. Pershing closes with reverse math: Val-gan need only trade at 7.4x 2014 pro-forma cash EPS to match Allergan's $116.63 unaffected price — implying substantial upside as the platform continues deploying capital across a $6tn healthcare opportunity set.
SCQA
Allergan is a high-quality specialty pharma franchise (Botox, eye care, aesthetics) but runs the traditional-pharma playbook: heavy fixed-cost R&D, bloated overhead, and a centralized operating model with mid-20s EBIT margins.
The same durable assets, lifted into Valeant's 'Outsider' platform — ~3% R&D, zero-based SG&A, decentralized country managers, and disciplined acquisition underwriting — would generate dramatically more cash per share than Allergan standalone.
Allergan should accept Valeant's cash-and-stock offer ($48.30 cash plus 0.83 Valeant shares per Allergan share), giving Allergan holders ~43% ownership of pro-forma Val-gan, with Pershing electing 100% stock.
Margin of safety is extreme: Val-gan needs to trade at only 7.4x 2014 pro-forma cash EPS to match Allergan's $116.63 unaffected price; cost synergies, organic growth, and continued M&A provide material upside beyond.
The three reasons
- 1
Valeant's Outsider-CEO model under Mike Pearson delivered 25x TSR (2,544%) in six years through disciplined M&A
- 2
~74% of Val-gan sales are durable, deserving Perrigo/Zoetis/global-beauty multiples (19x-24x P/E), not pharma multiples
- 3
Margin of safety is enormous: Val-gan need only trade at 7.4x 2014 cash EPS to match Allergan's $116.63 unaffected price
Primary demands
- Allergan shareholders should accept Valeant's cash-and-stock offer ($48.30 cash + 0.83 Valeant shares per Allergan share)
- Allergan board should engage with Valeant on the proposed business combination
- Recognize Valeant's 'Platform Value' and Outsider-CEO capital allocation model in the share price
KPIs cited
Pattern membership
Precedents cited
- The Outsiders (Buffett/Berkshire, Tom Murphy/Capital Cities, Henry Singleton/Teledyne, John Malone/TCI, Bill Stiritz/Ralston Purina, Katharine Graham/Washington Post, Dick Smith/General Cinema, Bill Anders/General Dynamics)
- Valeant's own integration track record (Biovail, Medicis, Bausch & Lomb)
- Reckitt Benckiser durable-OTC roll-ups (Boots Healthcare, Adams Respiratory, SSL, Schiff)
- J&J acquisition of Pfizer Consumer Health
Composition what's on the 110 slides
Slide gallery ·
Notes
Hybrid M&A activist deck: filed under SEC Rule 425 as Pershing Square's case to ALLERGAN shareholders to accept the joint Pershing-Valeant takeover bid. Unusual posture — Pershing is co-bidding WITH the acquirer rather than running a standalone activist campaign against Allergan management, so the rhetoric is constructive (an extended hagiography of Mike Pearson as the ninth 'Outsider' CEO in the Buffett/Singleton/Malone tradition) rather than adversarial. No direct attack on Allergan's CEO David Pyott by name — implicit villain is traditional-pharma R&D orthodoxy. Cover credits Pershing Square only; William Ackman is named in the SEC disclaimer participants list and the deck is universally attributed to him. Closing payoff is John Templeton's 'It is impossible to produce superior performance unless you do something different' (page 104) rather than a single-line CTA. The 'Platform Value' concept introduced here was novel and influential. Visually a clean institutional Pershing template (blue/green palette, diamond logo, readable charts) but heavy on text bullets; not Ackman-CP-2012 tier.